Ophtesic (Anhydrous Lidocaine Hydrochloride)

Lidocaine works by reversibly blocking voltage‑gated sodium channels on sensory nerve fibers in the cornea and conjunctiva. This blockade stops the initiation and propagation of nerve impulses, producing a temporary loss of sensation. The effect is concentration‑dependent, rapid in onset, and wears off shortly after the drug is cleared from the ocular surface.

The specific dose and frequency of Ophtesic are determined by the prescribing ophthalmologist based on the procedure and patient characteristics. Typically, a few drops are instilled onto the ocular surface shortly before the intended examination or intervention, but exact regimens should follow the clinician’s written instructions.

Safety data for lidocaine ophthalmic use in pregnancy and lactation are limited. Ophtesic should be used only if the potential therapeutic benefit justifies any potential risk to the fetus or infant. The prescriber should evaluate the individual situation and discuss possible alternatives when appropriate.

To place an order, submit an enquiry on the Ophtesic product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Ophtesic delivers lidocaine, a well‑studied amide‑type local anesthetic with a rapid onset and short duration, making it suitable for brief procedures. Compared with ester‑type agents such as proparacaine, lidocaine generally provides a slightly longer anesthetic window and a comparable safety profile, though individual patient response may vary.

Ophtesic should be stored at room temperature, below 25 °C, in its original sealed container. Protect the product from direct sunlight, excessive heat and moisture. Once opened, use the solution within the period recommended by the manufacturer and discard any remaining product after that time.

Ophtesic is applied as sterile eye drops. The prescriber or trained healthcare professional instills the recommended number of drops onto the conjunctival sac, typically a few minutes before the intended procedure. Patients should be instructed not to touch the dropper tip to the eye or any surface to maintain sterility.

Serious risks, although rare, include allergic reactions such as eyelid edema or angioedema, corneal epithelial injury, and systemic lidocaine toxicity that can manifest as central nervous system symptoms (e.g., dizziness, seizures) or cardiovascular effects. Prompt medical attention is required if any of these events occur.

Ophtesic should be avoided in individuals with a known hypersensitivity to lidocaine or any other component of the formulation. It is also contraindicated in patients with active ocular infections that have not been treated, and it should be used with caution in pregnant or breastfeeding women, children, and those on interacting systemic medications.